HomeProductsMaterials ScienceMOF LigandsNitrogen containing MOF ligandsTopiroxostat
Chemical structure of CAS 577778-58-6

Topiroxostat

CAS No.577778-58-6
MDL No.MFCD17167057
MFC13H8N6
MW248.24
InChI KeyUBVZQGOVTLIHLH-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.577778-58-6
Product NameTopiroxostat

Biological Targets

XDH

Associated Conditions

diabetic nephropathy·hyperuricemia
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout.

Clinical and experimental nephrology • Vol. 18, Issue 6 • 2014
PMID: 24448692PMC: PMC4271138DOI: 10.1007/s10157-014-0935-8

QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation.

Journal of clinical pharmacology • Vol. 54, Issue 4 • 2014
PMID: 24214189DOI: 10.1002/jcph.226

FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase.

The Journal of pharmacology and experimental therapeutics • Vol. 336, Issue 1 • 2011
PMID: 20952484DOI: 10.1124/jpet.110.174540

Study on species differences in nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor.

Archives of toxicology • Vol. 85, Issue 5 • 2011
PMID: 20936465DOI: 10.1007/s00204-010-0598-5

Documentation